Canaccord raised the firm’s price target on Artivion (AORT) to $41 from $35 and keeps a Buy rating on the shares. The firm said they posted a strong Q2 beat and raise driven by Aortic Stent Graft (AMDS) and On-X strength. Canaccord believes that Q2 is just the start for the company especially considering its deep pipeline of PMA products.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AORT: